Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

eMed vs Eve

eMed
Graded #399

Lower grade

vs+8.600000000000001
Eve
Graded #210

Higher grade

The verdict

Eve takes it — 66/100 to 57.4/100.

Eve grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Eve is a women's-health-focused GLP-1 telehealth platform — distinctive positioning in a largely gender-neutral market — offering both compounded semaglutide and tirzepatide (including an oral sublingual…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueEve +9
45
54
Dose & formulationEve +48
40
88
Clinical oversighteMed +4
83
79
Labs & monitoringeMed +13
65
52
FulfillmentEve +5
62
67
Contract termseMed +14
55
41
eMed · left barEve · right bar

The numbers

MetriceMedEve
WeighScore57.4/10066/100
GradeCC
Scorecard rank#399#210
SemaglutideNot disclosed$195/mo (compounded)
TirzepatideNot disclosed$195/mo (compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyYes
eMed

Graded #399 · C

Strengths

  • Prescribes FDA-approved branded GLP-1s (semaglutide and tirzepatide)
  • At-home blood collection makes lab work convenient
  • Clinician review and ongoing side-effect plus adherence support
  • Works with CVS Caremark so eligible employees can buy through benefits
  • Established digital health company with national scale

Where it loses points

  • Distributed mainly via employers, with limited direct cash-pay access
  • No public transparent monthly price for individuals
  • Eligibility and subsidy depend on what the employer chooses to cover
  • Best suited to workforces, not casual self-pay shoppers
Eve

Graded #210 · C

Strengths

  • Genuinely women's-health-focused — fills a real gap among gender-neutral GLP-1 competitors
  • Both compounded and brand-name FDA-approved options (Wegovy/Ozempic/Mounjaro) on one platform — rare
  • LegitScript Certified with a verifiable ID
  • Publishes the FDA compounded-medication disclaimer
  • Oral sublingual semaglutide offered alongside injectable

Where it loses points

  • Full states-served list not disclosed publicly
  • 503A pharmacy partner not named, and 503A vs 503B status not specified
  • Named medical director / clinical leadership not disclosed
  • Corporate legal entity not disclosed
  • Governing law / arbitration venue not stated

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard